Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 12/10/2025 at 15:00, 1 month 20 days ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026

Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea FDA Renewal
BRIEF

published on 12/08/2025 at 22:20, 1 month 21 days ago

Jaguar Health Announces Approval of Proposals at Stockholder Meeting

Crofelemer Microvillus Inclusion Disease FDA Approval Jaguar Health Stockholder Meeting
BRIEF

published on 12/08/2025 at 22:20, 1 month 21 days ago

Jaguar Health annonce l'approbation de propositions lors de l'assemblée générale des actionnaires

Crofelemer Jaguar Health Approbation De La FDA Assemblée Générale Des Actionnaires Maladie À Inclusions Microvillositaires
PRESS RELEASE

published on 12/08/2025 at 22:15, 1 month 21 days ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Jaguar CEO Lisa Conte to present updates on near-term catalysts at Emerging Growth Conference; Initial results show crofelemer may extend infants' lives with MVID; Jaguar completes FDA meeting on crofelemer trial for MVID treatment

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference MVID
BRIEF

published on 12/02/2025 at 15:05, 1 month 28 days ago

Jaguar Health Seeks EMA Approval for Canalevia to Treat Dog Diarrhea

Jaguar Health European Medicines Agency Dog Diarrhea Canalevia Approval Non-antibiotic Treatment
BRIEF

published on 12/02/2025 at 15:05, 1 month 28 days ago

Jaguar Health sollicite l'approbation de l'EMA pour Canalevia dans le traitement de la diarrhée canine

Jaguar Health Agence Européenne Des Médicaments Diarrhée Du Chien Approbation De Canalevia Traitement Non Antibiotique
PRESS RELEASE

published on 12/02/2025 at 15:00, 1 month 28 days ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap

Jaguar Health Dogs EMA Canalevia General Diarrhea
BRIEF

published on 11/24/2025 at 15:05, 2 months 6 days ago

Jaguar Health renforce sa propriété intellectuelle grâce à un nouveau brevet pour le crofélémère dans le traitement des troubles intestinaux.

Crofelemer Jaguar Health Essais Cliniques Brevet Troubles Intestinaux
BRIEF

published on 11/24/2025 at 15:05, 2 months 6 days ago

Jaguar Health Strengthens IP with New Patent for Crofelemer in Intestinal Disorders

Crofelemer Patent Clinical Trials Jaguar Health Intestinal Disorders
PRESS RELEASE

published on 11/24/2025 at 15:00, 2 months 6 days ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Jaguar Health, Inc. secures new patent expanding international IP for crofelemer in pediatric intestinal failure disorders, highlighting reductions in parenteral support. Supporting business development plans

Crofelemer Business Development Jaguar Health Inc. Pediatric Intestinal Failure New Patent

Published on 01/30/2026 at 14:00, 6 hours 11 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 11 hours 36 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 12 hours 11 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 17 hours 56 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 20 hours 11 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 20:07, 4 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 19:13, 58 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 1 hour 39 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 18:30, 1 hour 40 minutes ago

HOL-Holdings in Company
Published on 01/30/2026 at 18:23, 1 hour 47 minutes ago

TVR-Total Voting Rights

View all EQS

Published on 01/30/2026 at 18:40, 1 hour 31 minutes ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 2 hours 10 minutes ago

Emova Group - Résultats annuels 2024/25
Published on 01/30/2026 at 17:45, 2 hours 26 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 2 hours 26 minutes ago

Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 11 hours 41 minutes ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

View all LES ECHOS COMFI WIRE

News